Targeting the Biophysical Properties of the Myeloma Initiating Cell Niches: A Pharmaceutical Synergism Analysis Using Multi-Scale Agent-Based Modeling

Multiple myeloma, the second most common hematological cancer, is currently incurable due to refractory disease relapse and development of multiple drug resistance. We and others recently established the biophysical model that myeloma initiating (stem) cells (MICs) trigger the stiffening of their niches via SDF-1/CXCR4 paracrine; The stiffened niches then promote the colonogenesis of MICs and protect them from drug treatment. In this work we examined in silico the pharmaceutical potential of targeting MIC niche stiffness to facilitate cytotoxic chemotherapies. We first established a multi-scale agent-based model using the Markov Chain Monte Carlo approach to recapitulate the niche stiffness centric, pro-oncogenetic positive feedback loop between MICs and myeloma-associated bone marrow stromal cells (MBMSCs), and investigated the effects of such intercellular chemo-physical communications on myeloma development. Then we used AMD3100 (to interrupt the interactions between MICs and their stroma) and Bortezomib (a recently developed novel therapeutic agent) as representative drugs to examine if the biophysical properties of myeloma niches are drugable. Results showed that our model recaptured the key experimental observation that the MBMSCs were more sensitive to SDF-1 secreted by MICs, and provided stiffer niches for these initiating cells and promoted their proliferation and drug resistance. Drug synergism analysis suggested that AMD3100 treatment undermined the capability of MICs to modulate the bone marrow microenvironment, and thus re-sensitized myeloma to Bortezomib treatments. This work is also the first attempt to virtually visualize in 3D the dynamics of the bone marrow stiffness during myeloma development. In summary, we established a multi-scale model to facilitate the translation of the niche-stiffness centric myeloma model as well as experimental observations to possible clinical applications. We concluded that targeting the biophysical properties of stem cell niches is of high clinical potential since it may re-sensitize tumor initiating cells to chemotherapies and reduce risks of cancer relapse.

[1]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[2]  Sanjay Kumar,et al.  Mechanics, malignancy, and metastasis: The force journey of a tumor cell , 2009, Cancer and Metastasis Reviews.

[3]  Ling Xia,et al.  Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. , 2011, Journal of theoretical biology.

[4]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[5]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[6]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[7]  Youli Zu,et al.  Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. , 2010, Leukemia research.

[8]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[9]  Leslie M Loew,et al.  Computational cell biology: spatiotemporal simulation of cellular events. , 2002, Annual review of biophysics and biomolecular structure.

[10]  Monica A. Serban,et al.  Use of Hyaluronan‐Derived Hydrogels for Three‐Dimensional Cell Culture and Tumor Xenografts , 2008, Current protocols in cell biology.

[11]  C. Huff,et al.  Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma , 2007, Proceedings of the National Academy of Sciences.

[12]  Jake E. Delmore,et al.  Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. , 2011, Blood.

[13]  Jose L. Segovia-Juarez,et al.  Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. , 2004, Journal of theoretical biology.

[14]  Lu Gao,et al.  Multiple myeloma cancer stem cells , 2016, Oncotarget.

[15]  James A Bankson,et al.  Three-dimensional tissue culture based on magnetic cell levitation. , 2010, Nature nanotechnology.

[16]  Youli Zu,et al.  P38 MAPK inhibition enhancing ATO‐induced cytotoxicity against multiple myeloma cells , 2007, British journal of haematology.

[17]  J. Bladé,et al.  Changing paradigms in the treatment of multiple myeloma , 2009, Haematologica.

[18]  J. Au,et al.  Evaluation of Combination Chemotherapy , 2004, Clinical Cancer Research.

[19]  C. Huff,et al.  Characterization of clonogenic multiple myeloma cells. , 2004, Blood.

[20]  Kenneth C Anderson,et al.  Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. , 2007, Experimental hematology.

[21]  C. Chang,et al.  A Novel Multiparametric Approach for Analysis of Cytoplasmic Immunoglobulin Light Chains by Flow Cytometry , 2001, Modern Pathology.

[22]  Yongdong Feng,et al.  Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. , 2010, Stem cells and development.

[23]  A. Eastman,et al.  Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib , 2013, PloS one.

[24]  C. Huff,et al.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. , 2008, Cancer research.

[25]  K. Vanderkerken,et al.  Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. , 2008, Bulletin du cancer.

[26]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[27]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[28]  T. Deisboeck,et al.  Development of a three-dimensional multiscale agent-based tumor model: simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. , 2006, Journal of theoretical biology.

[29]  R. Ganguly,et al.  Mathematical model for the cancer stem cell hypothesis , 2006, Cell proliferation.

[30]  S. Jagannath,et al.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells , 2006, The Journal of experimental medicine.

[31]  W. Bensinger.  Role of autologous and allogeneic stem cell transplantation in myeloma , 2009, Leukemia.

[32]  M. Wicha,et al.  Symmetric Division of Cancer Stem Cells – a Key Mechanism in Tumor Growth that should be Targeted in Future Therapeutic Approaches , 2007, Clinical pharmacology and therapeutics.

[33]  Jerry C. Hu,et al.  Unique biomechanical interactions between myeloma cells and bone marrow stroma cells. , 2010, Progress in biophysics and molecular biology.

[34]  Charles P. Lin,et al.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.

[35]  J. Keats,et al.  Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. , 2002, Experimental hematology.

[36]  P. Maini,et al.  A mathematical model of the effects of hypoxia on the cell-cycle of normal and cancer cells. , 2004, Journal of theoretical biology.

[37]  F. Dammacco,et al.  Cancer Stem Cells in Multiple Myeloma , 2011 .

[38]  R. Tallarida,et al.  An Overview of Drug Combination Analysis with Isobolograms , 2006, Journal of Pharmacology and Experimental Therapeutics.

[39]  K. Anderson,et al.  Emerging Therapies for Multiple Myeloma , 2006, Expert opinion on emerging drugs.

[40]  G. Prestwich,et al.  Regulation of hepatic stem/progenitor phenotype by microenvironment stiffness in hydrogel models of the human liver stem cell niche. , 2011, Biomaterials.

[41]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[42]  W. Dalton,et al.  Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms , 2003, Leukemia.

[43]  Jing Su,et al.  Local cell metrics: a novel method for analysis of cell-cell interactions , 2009, BMC Bioinformatics.

[44]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  H. Tagawa,et al.  Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells , 2013, PloS one.